<DOC>
	<DOCNO>NCT02769884</DOCNO>
	<brief_summary>This study trial prototype artificial pancreas system consist Roche insulin pump , Dexcom continuous glucose monitor ( CGM ) , experiential MMPPC ( multiple model probabilistic predictive control ) algorithm house android cell phone . The system dose insulin base CGM sensor glucose level experimental algorithm . The aim clinical study determine efficacy MMPPC controller adolescent adult type 1 diabetes hotel setting .</brief_summary>
	<brief_title>MMPPC Outpatient Clinical Protocol 2016</brief_title>
	<detailed_description>This study trial prototype artificial pancreas system consist Roche insulin pump , Dexcom continuous glucose monitor ( CGM ) , experiential MMPPC ( multiple model probabilistic predictive control ) algorithm house android cell phone . The system dose insulin base CGM sensor glucose level experimental algorithm . The algorithm run glucose control platform call DiAs ( Diabetes Assistant ) The aim clinical study determine efficacy MMPPC controller adolescent adult type 1 diabetes hotel setting .</detailed_description>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>3.1 Eligibility Criteria 1 . Clinical diagnosis type 1 diabetes least 12 month 2 . Daily insulin therapy least 12 month 3 . Age 15.0 55.0 year age 4 . Use insulin pump least 3 month 5 . Current use continuous glucose monitoring Dexcom sensor 6 . Subject comprehend English 7 . Females childbearing potential must use adequate method contraception negative pregnancy test 8 . Total daily insulin requirement ≥ 0.3 units/kg/day 9 . A1C 7.0 10 % 3.2 Exclusion Criteria 1 . Diabetic ketoacidosis past 6 month 2 . Hypoglycemic seizure loss consciousness past 6 month 3 . Hypoglycemia unawareness define recognition hypoglycemia glucose &lt; 60 mg/dL adrenergic symptom glucose 60 mg/dL ( shakiness , palpitation , diaphoresis ) . Subjects also administer Clark questionnaire hypoglycemia unawareness . If score ≥ 4 , exclude study 4 . Subjects require intermediate longacting insulin ( NPH , detemir glargine ) 5 . Subjects use antidiabetic medication insulin ( oral injectable ) time enrollment . Any prior use antidiabetic medication must wash least 8 week prior enrollment . 6 . Current use medication , judgment investigator would contraindication participation study 7 . Subject medical disorder judgment investigator affect completion aspect protocol 8 . Subject currently participate another investigational device drug study within 30 day 5half life drug . 9 . Subject history cardiac vascular disorder include , limited , myocardial infarction , unstable angina , coronary artery bypass surgery , coronary artery stenting , transient ischemic attack , cerebrovascular accident , angina , congestive heart failure , arrhythmia thromboembolic disease 10 . An EKG obtain subject ≥ 45 year age , 20 year history diabetes ≥ 30 year age . Subjects exclude abnormal EKG consistent coronary artery disease increase risk malignant arrhythmia include , limited , evidence active ischemia , prior myocardial infarction , proximal LAD critical stenosis ( Wellen 's sign ) , prolong QT interval ( &gt; 440 m ) . Nonspecific ST segment T wave change ground exclusion absence symptom history heart disease . 11 . Subject history hepatic disease 12 . Subject renal failure dialysis 13 . Systolic blood pressure &gt; 160 mmHg screen visit 14 . Diastolic blood pressure &gt; 90 mmHg screen visit 15 . Subjects inadequately treat thyroid disease celiac disease 16 . Subject neurologic disorder judgment investigator affect completion protocol 17 . Subject receive inpatient psychiatric treatment past 6 month 18 . Subject consumes average 4 standard alcoholic drinks/day last 30 day 19 . Subject active skin condition would affect sensor placement 20 . Subject unable avoid acetaminophen duration study 21 . Subject consume less 100g carbohydrate daily</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>artificial pancreas</keyword>
</DOC>